Ph.D. in Oncology from Peking University Health Science Center; Visiting Scholar at the University of California, San Francisco (UCSF) Comprehensive Cancer Center. Chief Physician, Department of Breast Oncology, Peking University Cancer Hospital; Secretary of the Party Branch, Department of Breast Oncology; Member of the Clinical Research Management Committee, Peking University Cancer Hospital; Member of the Expert Committee on Genetic Testing, Peking University Cancer Hospital. Specializes in the medical treatment of breast cancer, with particular expertise in precision, individualized, comprehensive therapy based on chemotherapy, targeted therapy, endocrine therapy, and immunotherapy for early and advanced breast cancer. Emphasizes the holistic management of breast cancer patients. Has led multiple research projects funded by the Chinese Anti-Cancer Association, the Wu Jieping Medical Foundation, and the Beijing Medical Award Foundation. Has participated in over 100 global and national multicenter prospective clinical trials of new drugs and has published dozens of academic papers in domestic and international journals. As one of the lead writers, contributed to the compilation of the *First Chinese Consensus Guidelines on Advanced Breast Cancer*. Holds concurrent academic positions including Member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, Standing Committee Member of the Breast Disease Professional Committee of the Chinese Women Doctors Association, Standing Committee Member of the Oncology Clinical Research Professional Committee of the China Medical Education Association, Standing Committee Member of the Integrated Multidisciplinary Tumor Prevention and Treatment Professional Committee of the China Association for Research and Advancement of Chinese Traditional Medicine, and Standing Committee Member of the Breast Tumor Professional Committee of the Beijing Chronic Disease Prevention and Health Education Research Association. Primary research focus is on precision diagnosis and treatment of breast cancer. **Publications** Published 76 papers, including 41 SCI articles, with 15 as first author. 1. Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W. Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective Study. Breast Cancer (Dove Med Press). 2025 Jan 24;17:67-78. (Co-first author) 2. Liu J, Zhang J, Li H, Song G, Di L, Jiang H, Yan Y, Wang H, Wang J, Liu X, Shao B, Li Q. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer. 2025 Jan 3;25(1):9. 3. Tan Y, Peng Z, Jiang H, Ma F, Wang J, Zhang P, Li Q, Tian X, Han Y, Ji D, Xu B, Zhao W, Fan Y. Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study. Ther Adv Med Oncol. 2024 Nov 16;16:17588359241292256. 4. Liao Y, Tan Y, Li Y, Ma F, Wang J, Zhang P, Li Q, Li Q, Luo Y, Lan B, Chen S, Xu B, Jiang H, Zhao W, Fan Y. The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study. Heliyon. 2024 Sep 19;10(19):e38147. (Co-corresponding author) 5. Zhu A, Wang N, Yun Z, Liu X, Liang X, Yan Y, Shao B, Jiang H, Di L, Song G, Li H. HER2 status results in an unstable switch from primary to recurrent breast cancer. Neoplasma. 2024 Aug;71(4):392-401. 6. Jiang H, Zhong J, Wang J, Song G, Di L, Shao B, Zhang R, Liu Y, Zhu A, Wang N, Li H. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China. Cancer Med. 2024 May;13(10):e7249. 7. Zhong J, Jiang H, Liu X, Liao H, Xie F, Shao B, Jia S, Li H. Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Apr;204(3):617-629. 8. Wang H, Li H, Song G, Di L, Shao B, Jiang H, Liang X, Yan Y, Zhang R, Ran R, Zhang J, Liu Y, Liu X, Wang J. Clinical characteristics and treatment of breast cancer patients with interstitial lung disease [J]. Cancer Progress, 2024, 22 (03): 257-261. 9. Tan Y, Jiang H, Ma F, Wang J, Zhang P, Li Q, Tian X, Xu B, Zhao W, Fan Y. Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China. Thorac Cancer. 2023 Dec;14(34):3397-3405. (Co-first author) 10. Liu Y, Song G, Di L, Jiang H, Ran R, Zhang R, Zhang Y, Li H. Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study. Oncologist. 2023 Dec 11;28(12):1102-e1302. 11. Zhang R, Chen Y, Liu X, Gui X, Zhu A, Jiang H, Shao B, Liang X, Yan Y, Zhang J, Song G, Li H. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting. Front Oncol. 2023 Jun 16;13:1076469. 12. Jiang H, Li H, Song G, Di L, Shao B, Yan Y, Liu X, Chen Y, Zhang R, Ran R, Liu Y, Gui X, Wang N, Wang H. Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Res Treat. 2023 May;199(1):67-79. 13. Shao B, Li H, Liu X, Song G, Jiang H, Yan Y, Zhang R, Ran R, Zhang J, Liu Y, Wang H, Wang J, Di L. The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. Ann Transl Med. 2023 Jan 31;11(2):45. 14. Jiang H, Ouyang Q, Yin Y, Tong Z, Shen K, Yuan Z, Geng C, Liu Y, Song G, Ran R, Li W, Qu Q, Wang M, Meng L, Tong Y, Li H. Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. Eur J Cancer. 2022,176:1-12. 15. Shao B, Liu X, Li H, Song G, Di L, Jiang H, Yan Y, Zhang R, Ran R, Zhang J, Liu Y, Wang H, Wang J. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. Curr Oncol. 2022 Aug 25;29(9):6154-6166. 16. Shao B, Li H, Zhang J, Liu X, Song G, Jiang H, Yan Y, Wang H, Wang J, Di L. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR+HER2- metastatic breast cancer: a retrospective study. Ann Transl Med. 2022 Aug;10(16):901. 17. Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q, Jiang H, Zhao W, Lin F, Shao B, Yang X, Wu Z, Zhang T, Wang C, Guo Y. Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol. 2022 Aug 5;12:971594. 18. Zhu A, Yun Z, You M, Liu X, Liang X, Yan Y, Shao B, Jiang H, Di L, Song G, Li H. Surgical reduction in chest wall disease to prolong survival in breast cancer patients: a retrospective study. Gland Surg. 2022 Jun;11(6):1015-1025. 19. Zhang L, Song G, Shao B, Xu L, Xiao Y, Wang M, Sumou IK, Zhang Y, Liang X, Jiang H, Li H. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anticancer Drugs. 2022 Jan 1;33(1):e635-e643. 20. Jiang H, Zhang R, Liu X, Ran R, Zhang J, Liu Y, Gui X, Chen Y, Li K